Ganciclovir Glucose Injection

1. To prevent cytomegalovirus disease that may occur in organ transplant recipients who are at risk for cytomegalovirus infection; 2. To treat cytomegalovirus retinitis in immunocompromised patients (including AIDS patients);

(I) For patients with normal renal function: 1. Standard dose for the treatment of CMV retinitis: 1) Initial dose: 5 mg/kg, once every 12 hours, intravenous drip at a constant rate, each drip time is more than 1 hour, for 14 to 21 days. 2) Maintenance dose: 5 mg/kg, once a day, 7 days/week, intravenous drip at a constant rate, each drip time is more than 1 hour; or 6 mg/kg, once a day, 5 days/week, intravenous drip at a constant rate, each drip time is more than 1 hour. 2. Prevention of cytomegalovirus disease in organ transplant recipients: 1) Initial dose: 5 mg/kg, once every 12 hours, intravenous drip at a constant rate, each drip time is more than 1 hour, for 7 to 14 days. 2) Maintenance dose: 5 mg/kg, once a day, 7 days/week, intravenous drip at a constant rate, each drip time is more than 1 hour; or 6 mg/kg, once a day, 5 days/week, intravenous drip at a constant rate, each drip time is more than 1 hour. (II) Special medication instructions 1. Patients with renal insufficiency: For patients with renal insufficiency who receive hemodialysis, the dose should not exceed 1.25 mg/kg, 3 times a week, after hemodialysis. This product needs to be administered within a short period of time after the completion of hemodialysis, because hemodialysis can reduce the plasma concentration by about 50%. Since the dose adjustment is recommended for patients with renal insufficiency, their serum creatinine or creatinine clearance level should be closely monitored. 2. Patient monitoring: Due to the high frequency of granulocytopenia, anemia and thrombocytopenia in patients receiving ganciclovir (see adverse events), it is recommended to perform complete blood counts and platelet counts frequently, especially for those who have previously used ganciclovir or other nucleoside antagonists to develop hemocytopenia, or those whose neutrophil count is less than 1000/μL at the beginning of treatment. 3. Dose reduction: Patients with renal insufficiency need to reduce the dose. Consider reducing the dose for patients who develop neutropenia, anemia and/or thrombocytopenia (see adverse events). Ganciclovir should not be used in patients with severe neutropenia (ANC less than 500/μL) or severe thrombocytopenia (platelets less than 25,000/μL). Note: This product is only for intravenous infusion and cannot be injected intramuscularly. This product cannot be used for rapid intravenous injection or intravenous push injection, and cannot exceed the recommended dose or the recommended infusion rate.

It is contraindicated in patients who are allergic to ganciclovir or acyclovir.

100 ml: 0.1 g of ganciclovir and 5 g of glucose

Yuanda Medical Nutrition Science (Wuhan) Co., Ltd.

• Founded in:

  2003-08-04

• Address:

  No. 1, Xiaoxiang West Road, Dongxihu District, Wuhan City, Hubei Province

• Tax NO.:

  9142011275182772XJ

• Registered Funds:

  17.157 million yuan

• Website:

  Log in to view

• Email:

  Log in to view